Publications by authors named "F Toffalorio"
Article Synopsis
- Lorlatinib is a third-generation drug that effectively targets ALK and ROS1 tyrosine kinases in patients with advanced ALK-positive non-small cell lung cancer (NSCLC), showing promising long-term survival rates.
- The study involved 367 adults with varying treatment backgrounds who took lorlatinib daily and assessed response rates, overall survival (OS), and safety.
- Results indicated that patients had substantial improvements in OS across different treatment groups, with noted adverse events leading to dose adjustments in some cases, but the drug's safety profile remained generally stable over five years of follow-up.
What Is This Study About?: This is a summary of the results of an ongoing study called CROWN. In the CROWN study, researchers looked at the effects of two medicines called lorlatinib (Lorbrena) and crizotinib (Xalkori) for people with advanced non-small cell lung cancer (NSCLC) who had not been treated yet. Everyone in the study had changes in a called anaplastic lymphoma kinase, or , in their cancer cells.
View Article and Find Full Text PDFPurpose: Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, -positive non-small cell lung cancer (NSCLC) in the phase III CROWN study. Here, we report long-term outcomes from CROWN after 5 years of follow-up.
Methods: Two hundred ninety-six patients with -positive NSCLC were randomly assigned 1:1 to receive lorlatinib 100 mg once daily (n = 149) or crizotinib 250 mg twice daily (n = 147).
What Is This Summary About?: This summary shows the updated results of an ongoing research study called CROWN that was published in in December 2022. In the CROWN study, researchers looked at the effects of two study medicines called lorlatinib and crizotinib. The study included people with advanced non-small-cell lung cancer (NSCLC) that had not been treated previously.
View Article and Find Full Text PDFIntroduction: Circulating tumor DNA (ctDNA) has been used as a biomarker for prognostication and response to treatment. Here, we evaluate ctDNA as a potential biomarker for response to lorlatinib, a third-generation ALK tyrosine kinase inhibitor in patients with treatment-naive, advanced, ALK-positive NSCLC in the ongoing phase 3 CROWN study (NCT03052608).
Methods: Molecular responses were calculated using mean variant allele frequency (VAF), longitudinal mean change in VAF (dVAF), and ratio to baseline.